-Leverages Factor's extensively patented mRNA, cell-reprogramming, and gene-editing technologies-Cell therapy candidates will initially be developed for the treatment of Duchenne muscular dystrophy ('DMD')-Other planned applications include infectious, inflammatory, and autoimmune indicationsCAMBRIDGE, Mass., Jan.

-利用Factor广泛获得专利的mRNA，细胞重编程和基因编辑技术细胞治疗候选药物最初将用于治疗杜兴氏肌营养不良症（“DMD”）-其他计划应用包括传染性，炎症性和自身免疫性适应症马萨诸塞州坎布里奇，1月。

9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ('Factor'), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, announced the award of a U.S. Department of Defense grant to develop next-generation cell therapy candidates using Factor's patented mRNA, cell-reprogramming, and gene-editing technologies.

92024/PRNewswire/--Factor Bioscience Inc.（“Factor”）是一家位于马萨诸塞州剑桥的开发先进mRNA和细胞工程技术的生物技术公司，宣布授予美国国防部拨款，以开发使用Factor专利mRNA，细胞重编程和基因编辑技术的下一代细胞治疗候选药物。

The project will be led by Factor's Co-Founder and Chief Technology Officer, Dr. Christopher Rohde..

该项目将由Factor的联合创始人兼首席技术官ChristopherRohde博士领导。。

Continue Reading

继续阅读

'The recent approval of the first CRISPR gene-edited cell therapy has paved the way for the development of many new medicines made using state-of-the-art gene-editing technologies,' said Dr. Rohde. 'With the support of this grant, Factor will leverage its expertise in mRNA and therapeutic gene-editing technology development to advance the first mRNA gene-edited cell therapy platform toward commercialization.'.

Rohde博士说，最近批准的第一种CRISPR基因编辑细胞疗法为许多使用最先进的基因编辑技术制造的新药的开发铺平了道路在这笔赠款的支持下，Factor将利用其在mRNA和治疗性基因编辑技术开发方面的专业知识，推动第一个mRNA基因编辑的细胞治疗平台走向商业化。”。

Factor will leverage its expertise to advance the first mRNA gene-edited cell therapy platform toward commercialization.

Factor将利用其专业知识推动第一个mRNA基因编辑的细胞治疗平台走向商业化。

Post this

发布此

Under the award, Factor will generate the first scalable cell therapy specifically targeting muscle inflammation in DMD patients. To carry out the work, Factor will utilize its extensively patented technologies for engineering cells, including methods for reprogramming and gene-editing cells using mRNA..

根据该奖项，Factor将产生第一个专门针对DMD患者肌肉炎症的可扩展细胞疗法。为了开展这项工作，Factor将利用其广泛的工程细胞专利技术，包括使用mRNA重编程和基因编辑细胞的方法。。

'Cells are the building blocks of life, and disease is caused by cellular dysfunction,' said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. 'While every disease is unique, the link to cellular function provides opportunities to intervene in essentially any disease using cell engineering. As early innovators in the field of therapeutic cell engineering, we are excited to deploy these powerful technologies to develop new medicines to treat patients in need.'The award is sponsored by the Office of the Assistant Secretary of Defense for Health Affairs, through the Duchenne Muscular Dystrophy Research Program, which is endorsed by the Department of Defense.

Factor联合创始人、董事长兼首席执行官马特·安吉尔（MattAngel）博士说，细胞是生命的基石，疾病是由细胞功能障碍引起的虽然每种疾病都是独特的，但与细胞功能的联系提供了使用细胞工程干预基本上任何疾病的机会。作为治疗性细胞工程领域的早期创新者，我们很高兴能够部署这些强大的技术来开发新药来治疗有需要的患者。”该奖项由负责卫生事务的助理国防部长办公室通过国防部认可的杜兴氏肌营养不良症研究计划赞助。

The award will fund development activities for up to five years.About Factor BioscienceFactor Bioscience develops technologies for engineering cells to promote health and improve lives. For more information, visit www.factorbio.com.The contents of this press release do not necessarily represent the official view of the United States Department of Defense.SOURCE Factor Bioscience.

该奖项将资助长达五年的发展活动。关于因子生物科学因子生物科学开发工程细胞技术，以促进健康和改善生活。欲了解更多信息，请访问www.factorbio.com。本新闻稿的内容不一定代表美国国防部的官方观点。源因子生物科学。